亚盛迪斯制药获得了FDA的YORVIPATH®治疗低甲状腺症的7年市场独家权. Ascendis Pharma receives 7-year market exclusivity for hypoparathyroidism treatment YORVIPATH® from the FDA.

亚盛迪斯制药获得美国FDA的孤儿药物独家许可,用于治疗成人甲状腺功能低下症的YORVIPATH® (palopegteriparatide). Ascendis Pharma has obtained Orphan Drug Exclusivity from the U.S. FDA for YORVIPATH® (palopegteriparatide), a treatment for adult hypoparathyroidism. 这一指定赋予公司7年的市场独家经营权。 This designation grants the company seven years of market exclusivity. 美国YORVIPATH的约70 000至90 000人患有伪甲状腺病,目的是在24小时内持续提供荷尔蒙,Ascendis致力于及时向病人提供。 Hypoparathyroidism affects approximately 70,000 to 90,000 individuals in the U.S. YORVIPATH aims to provide consistent hormone delivery over 24 hours, with Ascendis working to make it available to patients promptly.